Accessibility Menu

Quantumzyme(OTC) QTZM

Current Price$0.11
Market Cap$4.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-89%
5 YearN/A
1 Year+2,100%
1 Month-39%
Quantumzyme last closing stock price
MetricPriceDate
Last closeUSD 0.112026-07-22
Quantumzyme stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10%USD 0.102026-07-15
1 month-38.89%USD 0.182026-06-22
3 month-8.33%USD 0.122026-04-22
Year to date-96.19%USD 2.892025-12-31
1 year+2,100%USD 0.012025-07-18
Since inception-88.79%USD 1.002024-11-20

Quantumzyme Financials at a Glance

Market Cap

$4.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$4.47M

EPS (TTM)

-$0.13

P/E Ratio

-0.89

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.11

Volume

12,200

Open

$0.11

Previous Close

$0.11

Daily Range

$0.11 - $0.11

52-Week Range

$0.00 - $5.04

Estimated Earnings Date

N/A

QTZM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quantumzyme

Quantumzyme Corp. is a biotransformation firm specializing in engineered enzymes for the production of active pharmaceutical ingredients (APIs). Established in 2015 and rebranded in March 2023, the company operates from San Diego, California.

Products and Services
  • Engineered enzymes for pharmaceutical applications
  • Custom enzyme development for various industries
  • Research and development in biotransformation technologies
Growth Outlook
  • Market demand for biotransformation solutions is increasing
  • Potential partnerships with pharmaceutical companies are being explored
  • Expansion into new markets is planned for the coming years
Financial Highlights
  • Recent quarterly net income reported at -$24,912
  • Trailing twelve months (TTM) revenue remains at $0
  • Current liabilities total $443,313, indicating financial challenges
Quantumzyme Corp. is positioned in a growing sector with increasing demand for biotransformation solutions. The company’s focus on engineered enzymes for pharmaceutical applications aligns with industry trends. However, financial challenges are evident, as indicated by the recent quarterly net income and TTM revenue figures. The exploration of partnerships and market expansion may provide future growth opportunities, but potential investors should consider the current financial landscape.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Naveen Krishna Rao Kulkarni

Website

www.quantumzymecorp.com

Headquarters

San Diego, CA 92127, US

QTZM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

997.31%

Return on Capital

N/A

Return on Assets

-7576610.17%

Earnings Yield

-1.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

40.97M

Volume

12.20K

Avg. Volume

49.47K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$120.11K

EBITDA

-$120.11K

Operating Cash Flow

-$98.01K

Capital Expenditure

-$3.00

Free Cash Flow

-$98.01K

Cash & ST Invst.

$59.00

Total Debt

$251.21K

Quantumzyme Performance Analysis

Quantumzyme annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31USD 0N/A
20232023-07-31USD 0N/A
20242024-07-31USD 0N/A
20252025-07-31USD 0N/A
Quantumzyme sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31N/A
Q12025-10-31N/A
Q22026-01-31N/A
Q32026-04-30N/A
Quantumzyme annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31USD -0.01N/A
20232023-07-31USD -0.08601.8%
20242024-07-31USD -0.01-93.4%
20252025-07-31USD -0.0111.8%
Quantumzyme sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31N/A
Q12025-10-31N/A
Q22026-01-31-9130.8%
Q32026-04-3099.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.59M

N/A

Employees

1

N/A

Net Income

-$24.91K

N/A

EBITDA

-$19.08K

N/A

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$59.00

-89.9%

Total Debt

$251.21K

+4.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$251.21K

+4.5%

Return on Assets

-75766.10%

N/A

Return on Invested Capital

27.10%

N/A

Free Cash Flow

-$19.14K

N/A

Operating Cash Flow

-$19.14K

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TSETrinseo PLC
$0.13-37.50%
YMATJ-Star Holding Co., Ltd. Ordinary Shares
$2.09-9.13%
SNESSenesTech, Inc.
$1.38-1.78%
FMSTForemost Clean Energy Ltd.
$1.71-14.07%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%

Questions About QTZM

What is the current price of Quantumzyme?

Quantumzyme is trading at $0.11 per share.

What is the 52-week range for Quantumzyme?

Over the past 52 weeks, Quantumzyme has traded between $0.00 and $5.04.

How much debt does Quantumzyme have?

As of the most recent reporting period, Quantumzyme reported total debt of $251.21K.

How much cash does Quantumzyme have on hand?

Quantumzyme reported $59.00 in cash and cash equivalents in its most recent financial results.

What is Quantumzyme’s dividend yield?

Quantumzyme does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services